Login
$CYRX
$18.41 +$0.62 (3.49%) Close

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
ASSETS
Current Assets:
Cash and cash equivalents
Short-term investments
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Current assets held for sale
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Intangible assets, net
Goodwill
Deposits
Deferred tax assets
Long-term assets held for sale
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable and other accrued expenses
Accrued compensation and related expenses
Deferred revenue
Current portion of operating lease liabilities
Current portion of finance lease liabilities
Current portion of convertible senior notes, net of discount of $0.5 million and $1.1 million, respectively
Current portion of notes payable
Current portion of contingent consideration
Current liabilities held for sale
Total current liabilities
Convertible senior notes, net of current portion and discount of $0 and $2.3 million, respectively
Notes payable, net of current portion
Operating lease liabilities, net of current portion
Finance lease liabilities, net of current portion
Deferred tax liabilities
Other long-term liabilities
Contingent consideration
Long-term liabilities held for sale
Total liabilities
Stockholders' Equity:
Preferred stock
Series C Preferred Stock
Common stock, $0.001 par value; 100,000,000 shares authorized; 50,648,491 and 49,850,793 issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total stockholders' equity
Total liabilities and stockholders' equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support